TY - JOUR
T1 - Effect of sitagliptin on glucose control in type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery
AU - Shah, Ankit
AU - Levesque, Kiarra
AU - Pierini, Esmeralda
AU - Rojas, Betsy
AU - Ahlers, Michael
AU - Stano, Sarah
AU - Holter, Marlena
AU - Dutia, Roxanne
AU - Belsley, Scott
AU - McGinty, James
AU - Laferrère, Blandine
N1 - Funding Information:
A. S. was supported by the Endocrine Fellows Foundation and NIH T32 DK007271. R. D. was supported by NIH 7T32 DK007559-25. The study was funded by Merck Sharp & Dohme Corporation Investigator Initiated Study. Other sources of funding include NIH P30DK26687-30, P30DK063608, the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number UL1 TR000040. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Funding Information:
We thank the bariatric team from Weill Cornell and Mount Sinai St Luke's Hospital, and Dr Daniel Donovan for referring participants. None declared. A. S. contributed to data analysis and interpretation and drafted and edited this manuscript. K. L. contributed to data collection, analysis and interpretation and edited the manuscript. A. S. and K. L. contributed equally to the manuscript. E. P., B. R., M. A., S. S., M. H., R. D., participated in data collection and edited the manuscript. S. B. and J. M. referred participants and edited the manuscript. B. L. designed the study, supervised the data analysis, interpreted the data and wrote and edited the manuscript. B. L. is the guarantor of this work, and, as such, had full access to all the data and take responsibility for the integrity of the data and accuracy of the data analysis. Part of this work was presented as an oral presentation at the American Diabetes Association Meeting in San Diego, CA in June 2017.
Publisher Copyright:
© 2017 John Wiley & Sons Ltd
PY - 2018/4
Y1 - 2018/4
N2 - The present study was a 4-week randomized trial to assess the efficacy and safety of sitagliptin, a dipeptidyl-peptidase-4 inhibitor, in persistent or recurring type 2 diabetes after Roux-en-Y gastric bypass surgery (RYGB). Participants (n = 32) completed a mixed meal test (MMT) and self-monitoring of plasma glucose (SMPG) before and 4 weeks after randomization to either sitagliptin 100 mg daily or placebo daily. Questionnaires were administered to assess gastrointestinal discomfort. Outcome variables were glucose, active glucagon-like peptide-1 and β-cell function during the MMT, and glucose levels during SMPG. Age (56.3 ± 8.2 years), body mass index (34.4 ± 6.7 kg/m2), glycated haemoglobin (7.21 ± 0.77%), diabetes duration (12.9 ± 10.0 years), years since RYGB (5.6 ± 3.3 years) and β-cell function did not differ between the placebo and sitagliptin groups at pre-intervention. Sitagliptin was well tolerated, decreased postprandial glucose levels during the MMT (from 8.31 ± 1.92 mmol/L to 7.67 ± 1.59 mmol/L, P = 0.03) and mean SMPG levels, but had no effect on β-cell function. In patients with diabetes and mild hyperglycemia after RYGB, a short course of sitagliptin provided a small but significant glucose-lowering effect, with no identified improvement in β-cell function.
AB - The present study was a 4-week randomized trial to assess the efficacy and safety of sitagliptin, a dipeptidyl-peptidase-4 inhibitor, in persistent or recurring type 2 diabetes after Roux-en-Y gastric bypass surgery (RYGB). Participants (n = 32) completed a mixed meal test (MMT) and self-monitoring of plasma glucose (SMPG) before and 4 weeks after randomization to either sitagliptin 100 mg daily or placebo daily. Questionnaires were administered to assess gastrointestinal discomfort. Outcome variables were glucose, active glucagon-like peptide-1 and β-cell function during the MMT, and glucose levels during SMPG. Age (56.3 ± 8.2 years), body mass index (34.4 ± 6.7 kg/m2), glycated haemoglobin (7.21 ± 0.77%), diabetes duration (12.9 ± 10.0 years), years since RYGB (5.6 ± 3.3 years) and β-cell function did not differ between the placebo and sitagliptin groups at pre-intervention. Sitagliptin was well tolerated, decreased postprandial glucose levels during the MMT (from 8.31 ± 1.92 mmol/L to 7.67 ± 1.59 mmol/L, P = 0.03) and mean SMPG levels, but had no effect on β-cell function. In patients with diabetes and mild hyperglycemia after RYGB, a short course of sitagliptin provided a small but significant glucose-lowering effect, with no identified improvement in β-cell function.
KW - dipeptidyl-peptidase 4 inhibitor
KW - gastric bypass
KW - type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85043517970&partnerID=8YFLogxK
U2 - 10.1111/dom.13139
DO - 10.1111/dom.13139
M3 - Article
C2 - 29072800
AN - SCOPUS:85043517970
VL - 20
SP - 1018
EP - 1023
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
SN - 1462-8902
IS - 4
ER -